TARGET AUDIENCE
This program is intended for medical oncologists, hematologists, hematology-oncology fellows and other allied healthcare professionals involved in the treatment of breast cancer.

LEARNING OBJECTIVES

• Evaluate the results of genomic assays and other relevant patient- and treatment-related factors to personalize adjuvant systemic therapy for newly diagnosed ER-positive, HER2-negative, lymph node-negative or node-positive breast cancer.
• Comprehend available findings with CDK4/6 inhibitors for localized ER-positive, HER2-negative breast cancer, and assess the current role of these agents as a component of adjuvant treatment.
• Individualize the selection and sequence of systemic therapy for patients with ER-positive metastatic breast cancer (mBC), considering clinical presentation (eg, age, menopausal status, comorbidities, extent and sites of disease, biomarker status), prior treatment course and psychosocial status.
• Appraise available research data with commercially available CDK4/6 inhibitors in the treatment of ER-positive mBC, and optimally incorporate these agents into patient care.
• Employ evidence-based approaches in the treatment of ER-positive, HER2-negative, PIK3CA-mutated disease.
• Appreciate published efficacy and safety data with PARP inhibitors for patients with localized or metastatic breast cancer harboring BRCA1/2 mutations, and consider the diagnostic and therapeutic implications for nonresearch care.
• Recall the incidence and clinical relevance of ER-positive, HER2-low mBC, and understand currently available and emerging management approaches for this disease subset.
• Assess ongoing clinical studies evaluating novel agents and treatment strategies under development for ER-positive breast cancer, and counsel patients about the potential benefits of trial participation.

ACCREDITATION STATEMENT
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT
CME credit is no longer available for this issue

AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
CME credit is no longer available for this issue

Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

HOW TO USE THIS CME ACTIVITY
Video Program: This CME activity consists of a video component.
CME credit is no longer available for this issue

CONTENT VALIDATION AND DISCLOSURES
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

Aditya Bardia, MD, MPH
Director, Breast Cancer Research Program
Associate Professor
Harvard Medical School
Attending Physician
Massachusetts General Hospital
Boston, Massachusetts

Consulting Agreements: AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Foundation Medicine, Genentech, a member of the Roche Group, Gilead Sciences Inc, Lilly, Merck, Novartis, Pfizer Inc, Phillips HealthCare Services Ltd, Radius Health Inc, Sanofi; Contracted Research: AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, Lilly, Merck, Novartis, Pfizer Inc, Radius Health Inc, Sanofi.

Matthew P Goetz, MD
Erivan K Haub Family Professor of Cancer Research Honoring Richard F Emslander, MD
Professor of Oncology and Pharmacology
Enterprise Deputy Director, Translational Research
Director, Mayo Clinic Breast Cancer SPORE
Mayo Clinic
Rochester, Minnesota

Advisory Committee: ARC Therapeutics, Biotheranostics Inc, Blueprint Medicines, Sanofi; Consulting Agreements: AstraZeneca Pharmaceuticals LP, Biovica, Context Therapeutics, Eagle Pharmaceuticals, Lilly, Novartis, Pfizer Inc; Contracted Research: Lilly, Pfizer Inc, Sermonix Pharmaceuticals; Nonrelevant Financial Relationship (CME Presentation Fees): Clinical Education Alliance, Medscape, MJH Life Sciences; Nonrelevant Financial Relationship (Panelist): Total Health Conferencing.

Virginia Kaklamani, MD, DSc
Professor of Medicine
Ruth McLean Bowman Bowers Chair in Breast Cancer Research and Treatment
AB Alexander Distinguished Chair in Oncology
Associate Director for Clinical Research
Leader of the Breast Cancer Program
UT Health San Antonio
The University of Texas MD Anderson Cancer Center
San Antonio, Texas

Advisory Committee and Consulting Agreements: AstraZeneca Pharmaceuticals LP, Athenex, Gilead Sciences Inc, Puma Biotechnology Inc; Contracted Research: Eisai Inc; Data and Safety Monitoring Board/Committee: Sanofi; Speakers Bureau: AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Exact Sciences Corporation, Genentech, a member of the Roche Group, Gilead Sciences Inc, Novartis, Pfizer Inc, Seagen Inc.

Kevin Kalinsky, MD, MS
Associate Professor
Department of Hematology and Medical Oncology
Emory University School of Medicine
Director, Glenn Family Breast Center
Director, Breast Medical Oncology
Winship Cancer Institute of Emory University
Atlanta, Georgia

Advisory Committee: 4D Pharma PLC, AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Gilead Sciences Inc, Lilly, Menarini Silicon Biosystems, Merck, Mersana Therapeutics Inc, Myovant Sciences, Novartis, OncoSec Medical, Pfizer Inc, Puma Biotechnology Inc, Seagen Inc, Takeda Pharmaceuticals USA Inc; Contracted Research: Ascentage Pharma, AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, Lilly, Novartis; Data and Safety Monitoring Board/Committee: Merck.

Hope S Rugo, MD
Professor of Medicine
Director, Breast Oncology and Clinical Trials Education
University of California, San Francisco
Helen Diller Family Comprehensive Cancer Center
San Francisco, California

Consultancy/Advisory Support: Blueprint Medicines, Napo Pharmaceuticals Inc, Puma Biotechnology Inc; Contracted Research: Ambrx, Astellas, AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, GlaxoSmithKline, Lilly, Merck, Novartis, OBI Pharma Inc, Pfizer Inc, Pionyr Immunotherapeutics, Seagen Inc, Sermonix Pharmaceuticals, Taiho Oncology Inc, Veru Inc; Travel Support to Academic Meetings: AstraZeneca Pharmaceuticals LP, Gilead Sciences Inc, Merck.

MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI BioPharma Corp, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Corporation, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Kronos Bio Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc and Zymeworks Inc.

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Exact Sciences Corporation, Lilly, Novartis, Sanofi, and TerSera Therapeutics LLC.

Release date: January 2023
Expiration date: January 2024